Wadhane Jitendra
Known title: Chief Accounting OfficerCIK: 0001941706
Wadhane Jitendra's purchase track record
Wadhane Jitendra has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/22/2023 | PYXS | $18K | +5.3% | +149.4% | +21.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PYXS | ▲ Buy | Grant | 109,461 | $0 | 3/24/2026 | View on chart |
| PYXS | ▲ Buy | Grant | 131,484 | $0 | 3/26/2024 | View on chart |
| PYXS | ▲ Buy | Grant | 40,000 | $0 | 11/15/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 2,500 | $5K | 9/27/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 5,000 | $9K | 9/25/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 2,500 | $4K | 9/22/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 93,896 | $0 | 9/7/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 29,393 | $0 | 3/24/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 45,000 | $0 | 3/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.